Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Eli Lilly

NYSE:LLYPharma

Indianapolis, IN, United States · Est. 1876 · 43,000 employees

Global healthcare leader creating medicines that make life better.

89

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

104

Indications↗

Distinct diseases across all programs

2,207

Clinical Trials↗

All sponsored trials (all statuses)

47

Orange Book Patents

Across 9 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

89 drugs in development

Approved2

Phase 318

Phase 249

Phase 134

Preclinical4

By Therapeutic Area

top 6

Oncology

2721%

Metabolic & Endocrine

2318%

Immunology

1512%

Musculoskeletal

1210%

Neurology

1210%

Gastroenterology

86%

R&D Momentum

100/100

Pipeline Velocity

85/100

Trial Completion Rate

92/100

Pipeline Concentration

13/100

Pipeline Freshness

74/100

Strategic Signals

↗Active in Psychiatry but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Active, not recruiting

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

An Open Label, Randomized, Single Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics of Pre-filled Syringe Versus Vial Formulations of AM0010 in Healthy Adult Subjects

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy

A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Active, not recruiting

A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Details

Company Info

Company Overview

$750.0B

Mkt Cap

$34.1B

Revenue

$3.6B

Cash

CEODavid Ricks

Founded1876

Employees43,000

HQIndianapolis, IN, United States

ExchangeNYSE:LLY

Websitelilly.com

LinkedInCompany Page

Therapeutic Focus

Metabolic & EndocrineOncologyImmunologyNeurologyCardiovascularNephrologyDermatologyRespiratoryInfectious DiseaseOtherMusculoskeletalPsychiatryGastroenterologyHematologyOphthalmologyRare Disease

Patent Expirations

20 patent groups across drugs · Source: FDA Orange Book

DrugExpires

ReyvowFeb 17, 2028 OlumiantMar 10, 2029 ReyvowJul 7, 2030 VerzenioSep 28, 2031 Olumiant2 patentsNov 2, 2031 Olumiant3 patentsMay 31, 2032 MounjaroJan 5, 2036 Jaypirca5 patentsDec 16, 2036

12 more

FoundayoSep 26, 2037 Retevmo3 patentsOct 10, 2037 ReyvowDec 5, 2037 Retevmo6 patentsApr 10, 2038 Cialis4 patentsDec 24, 2038 Retevmo3 patentsApr 10, 2039 Mounjaro8 patentsJun 14, 2039 Inluriyo2 patentsJul 11, 2039 JaypircaJul 29, 2039 ReyvowJul 6, 2040 JaypircaSep 14, 2041 MounjaroDec 30, 2041

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(3 drugs)

—

—

—

3

—

Cardiovascular(3 drugs)

Dermatology(2 drugs)

—

—

1

1

—

Dermatology(2 drugs)

Gastroenterology(8 drugs)

—

—

6

2

1

Gastroenterology(8 drugs)

Immunology(15 drugs)

1

2

9

4

—

Immunology(15 drugs)

Metabolic & Endocrine(23 drugs)

2

10

16

3

1

Metabolic & Endocrine(23 drugs)

Musculoskeletal(12 drugs)

—

—

9

3

—

Musculoskeletal(12 drugs)

Nephrology(4 drugs)

—

2

3

—

—

Nephrology(4 drugs)

Neurology(12 drugs)

—

3

10

—

—

Neurology(12 drugs)

Oncology(27 drugs)

1

17

7

6

—

Oncology(27 drugs)

Psychiatry(2 drugs)

—

—

1

2

—

Psychiatry(2 drugs)

Respiratory(5 drugs)

—

—

1

4

—

Respiratory(5 drugs)

Unknown / Other(13 drugs)

—

2

9

2

1

Unknown / Other(13 drugs)

Regulatory

Regulatory Timeline

20161 event

FDAMar 22

Taltz — TALTZ

Application BLA125521 (BLA)

20172 events

FDADec 11

Humalog — ADMELOG

Application BLA209196 (BLA)

FDASep 28

Verzenio — VERZENIO

Application NDA208716 (NDA)

20181 event

FDASep 27

Emgality — EMGALITY

Application BLA761063 (BLA)

20191 event

FDAOct 8

Olumiant — OLUMIANT

Application NDA207924 (NDA)

20203 events

FDAJun 15

LYUMJEV — LYUMJEV

Application BLA761109 (BLA)

FDAMay 8

Retevmo — RETEVMO

Application NDA213246 (NDA)

FDAJan 31

Reyvow — REYVOW

Application NDA211280 (NDA)

20221 event

FDAJun 17

Cialis — TADLIQ

Application NDA214522 (NDA)

20233 events

FDAOct 26

Omvoh — OMVOH

Application BLA761279 (BLA)

FDAJul 28

Mounjaro — MOUNJARO

Application NDA215866 (NDA)

FDAJan 27

Jaypirca — JAYPIRCA

Application NDA216059 (NDA)

20245 events

FDASep 13

EBGLYSS — EBGLYSS

Application BLA761306 (BLA)

FDAJul 2

Kisunla — KISUNLA

Application BLA761248 (BLA)

FDAJun 28

Cialis — CHEWTADZY

Application NDA218527 (NDA)

FDAApr 10

Retevmo — RETEVMO

Application NDA218160 (NDA)

FDAMar 28

Mounjaro — ZEPBOUND

Application NDA217806 (NDA)

20251 event

FDASep 25

Inluriyo — INLURIYO

Application NDA218881 (NDA)

20262 events

FDAApr 1

Foundayo — FOUNDAYO

Application NDA220934 (NDA)

FDAJan 26

Folvite — QUIOFIC

Application NDA216395 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)